ATLANTA, GA – – (October 4, 2018) – – Holzer & Holzer, LLC is investigating whether Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) complied with the federal securities laws. On October 1, 2018, Plainview LLC published a report raising questions about Nektar’s claims concerning its clinical stage drug, NKTR-214, and its ability to effectively treat cancer. The price of Nektar common stock fell significantly following these reports. If you purchased Nektar common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or call the firm by toll-free telephone at (888) 508-6832.